# Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)

> **NCT06796998** · PHASE2 · RECRUITING · sponsor: **Izidore Lossos, MD** · enrollment: 25 (estimated)

## Conditions studied

- Marginal Zone Lymphoma
- Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Splenic Marginal Zone Lymphoma
- Nodal Marginal Zone Lymphoma

## Interventions

- **BIOLOGICAL:** Epcoritamab

## Key facts

- **NCT ID:** NCT06796998
- **Lead sponsor:** Izidore Lossos, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-13
- **Primary completion:** 2028-10-15
- **Final completion:** 2031-04-15
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-10-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06796998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06796998, "Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06796998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*